跳至主要内容
临床试验/NCT05962229
NCT05962229招募中1 期

Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

University of California, San Francisco2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2024年12月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
入组人数
18
试验地点
2
主要终点
Mean Nicotine Exposure Over Time

研究概览

简要总结

In a crossover study, experienced electronic cigarette users will vape 3 different forms of nicotine: natural (derived from tobacco), synthetic, or a 50:50 mixture of both natural and synthetic. The investigators will compare nicotine metabolism, cardiovascular effects, patterns of self-administration, and participants' feelings of craving/withdrawal and enjoyment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Single (Participant)

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy on the basis of medical history and limited physical examination.
  • Current regular user of E-Cigarettes (≥ 15 days in the past 30 days)

排除标准

  • • Medications
  • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
  • Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
  • Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
  • Any stimulant medications (example: Adderall) generally given for ADHD treatment.
  • Pregnancy
  • Pregnancy (self-reported and urine pregnancy test)
  • Breastfeeding (determined by self-report)
  • Women of childbearing potential must be using an acceptable method of contraception
  • Inability to read and write in English
  • A known propylene glycol/vegetable glycerin allergy
  • Uncomfortable with getting blood drawn

研究组 & 干预措施

S-nicotine (tobacco) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.

干预措施: (S)-Nicotine (Drug)

Racemic (50:50 S- and R- nicotine) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.

干预措施: (R)- nicotine (Drug)

S-nicotine (tobacco) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.

干预措施: (R)- nicotine (Drug)

S-nicotine (tobacco) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (S)-nicotine.

干预措施: Racemic nicotine (Drug)

R-nicotine (synthetic) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.

干预措施: (S)-Nicotine (Drug)

R-nicotine (synthetic) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.

干预措施: (R)- nicotine (Drug)

R-nicotine (synthetic) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 100% (R)-nicotine.

干预措施: Racemic nicotine (Drug)

Racemic (50:50 S- and R- nicotine) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.

干预措施: (S)-Nicotine (Drug)

Racemic (50:50 S- and R- nicotine) as the starting condition

Experimental

Participants will spend 8 hours in the hospital research ward where they will vape e-liquid containing 50% (S)-nicotine and 50% (R)-nicotine.

干预措施: Racemic nicotine (Drug)

结局指标

主要结局

Mean Nicotine Exposure Over Time

时间窗: Up to 7 hours

Plasma nicotine area under the concentrated time curve (AUC) (ng/ml\*h)

次要结局

  • Mean Amount of Nicotine Consumed Over Time(120 minutes)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验